Abstract
Abstract Background Validation studies demonstrated that the 12-RS assay, known as Oncotype DX Colon Cancer Assay, can identify a wide range of recurrence risk in stage II/III colon cancer (CC). The objective of this prospective study was to evaluate the decision impact of the 12-RS assay on adjuvant chemotherapy recommendation for stage II/III CC patients (UMI28784). Method Patients who had curatively resected stage II, IIIA or IIIB CC were eligible. Physicians formulated a treatment recommendation and completed a pre-assay questionnaire, and then the 12-RS assay was performed. Following receipt of the 12-RS result, the treatment recommendation was revised in a post-assay questionnaire. The primary endpoint was the proportion of changes in a treatment recommendation between pre- and post- assay. The threshold value for the proportion of changes was assumed 20%. The target enrollment was 300 patients (100 stage II and 200 stage III CC). Results Between November 2017 and January 2019, 305 patients were registered from 14 centers. Of 275 who were evaluable, stage II/III was 97/178 patients. The RS Conclusions This is the first study to evaluate the impact of the 12-RS assay on adjuvant treatment recommendations for stage III CC. The 12-RS results significantly influenced treatment recommendations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
